Bortezomib (VELCADE®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits

Autor: Yang, C.H., Gonzalez-Angulo, A.M., Reuben, J.M., Booser, D.J., Pusztai, L., Krishnamurthy, S., Esseltine, D., Stec, J., Broglio, K.R., Islam, R., Hortobagyi, G.N., Cristofanilli, M. ^*

Publikováno v: In Annals of Oncology May 2006 17(5):813-817

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Autor: Coiffier, B, Osmanov, E, Hong, X, Scheliga, A, Mayer, J, Offner, F, Rule, S, Teixeira, A, Walewski, J, de Vos, S, Crump, M, Shpilberg, O, Esseltine, D, Zhu, E, Enny, C, Theocharous, P, van de Velde, H, Elsayed, Y, Zinzani, P, Abdulkadyrov, K, Afanasiev, B, Aguayo Gonzalez, A, Andre, M, Belada, D, Ben Yehuda, D, Bezares, R, Biakhov, M, Bolam, S, Borbenyi, Z, Bron, D, Buckstein, R, Bumbea, H, Caballero Barrigon, M, Campos, L, Cantonetti, M, Capra Zanella, M, Christiansen, N, Cohen, G, Colita, N, Cosgriff, T, Culligan, D, Del Giglio, A, Dichmann, R, Dietzfelbinger, H, Digumarti, R, Dmoszynska, A, Domnikova, N, Dubinsky, P, Dunaev, Y, Easow, J, Eberwine, S, Economopoulos, T, Egyed, M, Ellerton, J, Eom, H, Farmer, L, Fenske, T, Fields, P, Fillet, G, Frank, R, Gaisarova, G, Garicochea, B, Gasztonyi, Z, Gavish, I, Gheorghita, E, Gladkov, O, Goldberg, V, Golenkov, A, Gomez Almaguer, D, Gonzalez Barca, E, Guan, Z, Gupta, S, Hellmann, A, Hermann, R, Honkanen, T, Hu, E, Huang, X, Hudecek, J, Illes, A, Intragumtornchai, T, Jedrzejczak, W, Jones, L, Jootar, S, Kahanic, S, Karamanesht, E, Ke, X, Khuageva, N, Kim, W, Kimby, E, Komisarenko, V, Kouroukis, T, Kuliczkowski, K, Kuzina, L, Kyselyova, M, Labanca, V, Lange, A, Le Gouill, S, Leahy, M, Liberati, A, Linden, O, Liu, T, Lubennikov, V, Lundin, J, Lysa, T, Lysenko, I, Lytvyn, I, Makhson, A, Manikhas, G, Masliak, Z, Mcintyre, R, Medvedeva, N, Mena, R, Merkulov, V, Mesters, R, Milpied, N, Min, Y, Moezi, M, Mohrbacher, A, Mollee, P, Morgan, D, Morschhauser, F, Mysanikov, A, Nagler, A, Nair, S, Naparstek, E, Nawarawong, W, Noga, S, Oliveira, I, Okada, C, Oriol Rocafiguera, A, Page, R, Papajik, T, Pasquini, R, Patel, M, Patel, R, Paton, E, Pavlov, V, Pospelova, T, Prasad, S, Pylypenko, H, Raposo, J, Rekhtman, G, Rivas, S, Robak, T, Saba, S, Salles, G, Saltzman, M, Samoilova, O, Samuels, B, Sanani, S, Sebban, C, Silva da Gomes, M, Shen, Z, Shi, Y, Shtalrid, M, Siritanaratkul, N, Skotnicki, A, Solal Celigny, P, Soubeyran, P, Spencer, A, Stevens, D, Suh, C, Sulek, K, Suvorov, A, Szer, J, Theunissen, K, To Bik, L, Tothova, E, Trneny, M, Van De Velde, A, Van Hoof, A, Van Steenweghen, S, Vanhatalo, S, Varma, S, Vidyasagar, M, Vilchevskaya, K, Vitolo, U, Wang, H, Warzocha, K, Wild, A, Zachee, P, Zanichelli, M, Zhang, W, Zoppegno, L, Zoumbos, N

Publikováno v: The Lancet. Oncology. 12(8)

BACKGROUND: Bortezomib and rituximab have shown additive activity in preclinical models of lymphoma, and have been shown to be active and generally well tolerated in a randomised phase 2 study in patients with follicular and marginal zone lymphoma. W

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a13b94128df5db75a9919f1ae0f67a71
https://pubmed.ncbi.nlm.nih.gov/21724461

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study

Autor: Dimopoulos, M.A. Mateos, M.-V. Richardson, P.G. Schlag, R. Khuageva, N.K. Shpilberg, O. Kropff, M. Spicka, I. Palumbo, A. Wu, K.L. Esseltine, D.-L. Liu, K. Deraedt, W. Cakana, A. Van De Velde, H. San Miguel, J.F.

Objectives: This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients with multiple myelom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::a429522d22b582aead691d2c345a88dc
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3130039

Time To Next Anti-lymphoma Therapy (ttnt) and Treatment-free Interval (tfi) With Bortezomib-rituximab (vcr) Vs Rituximab (r) In Patients (pts) With Relapsed Follicular Lymphoma (fl)

Autor: Kimby, E., Scheliga, A., Mayer, J., Offner, F., Teixeira, A., Kuliczkowski, K., Liberati, Anna Marina, Okada, C. Y., Esseltine, D., Theocharous, P., Zhu, E., H. V., De, Elsayed, Y. A., Coiffier, B.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3982::730c09b96f233d56cfc6b47c2119bb81
http://hdl.handle.net/11391/1010475

Superior Survival with VMP Versus MP After Longer Follow-up and Response to Subsequent Therapy in VISTA

Autor: San Miguel, J. Dimopoulos, M. A. Schlag, R. Khuageva, N. and Shpilberg, O. Kropff, M. Spicka, I. Petrucci, M. and Palumbo, A. Samoilova, O. Dmoszynska, A. Abdulkadyrov, K. and Schots, R. Jiang, B. Mateos, M. V. Anderson, K. C. and Esseltine, D. L. Liu, K. Cakana, A. van de Velde, H. and Richardson, P. G.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::d9b64330a5ca07e627bfe4a464d41d97
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3141499